Hamamoto T, Foster D C, Kisiel W
Department of Pathology, University of New Mexico School of Medicine, Albuquerque 87131, USA.
Int J Hematol. 1996 Jan;63(1):51-63. doi: 10.1016/0925-5710(95)00422-x.
Previous studies have shown that antithrombin III-heparin effectively inhibited the factor VIIa-tissue factor complex. Herein, we show that the neutralization of factor VIIa in complex with the cell surface tissue factor by antithrombin III-heparin was markedly enhanced by plasma levels of factor X. Active site-mutated factor X (S376A factor X) and factor Xa previously inactivated with dansyl-Glu-Gly-Arg-chloromethyl ketone were as effective as plasma-derived factor X in this reaction, indicating that the active site serine residue of factor Xa was not involved in this mechanism. Furthermore, Gla-domainless factor X had no effect in this system, emphasizing the importance of the factor X Gladomain in this reaction. Antibody experiments revealed that this effect was not due to trace levels of a tissue factor pathway inhibitor contaminating either the factor X or antithrombin III preparations. The presence of heparin in this system was essential, as deletion of heparin resulted in a factor VIIa-tissue factor neutralization rate essentially identical to that observed for antithrombin III alone. Plasma levels of factor IX also accelerated the inhibition of factor VIIa-tissue factor by antithrombin III-heparin, although its effect was not as pronounced as that of factor X. Other vitamin K-dependent plasma proteins including protein S, protein C and prothrombin failed to augment the inhibition of factor VIIa-tissue factor by antithrombin III-heparin. Factor X did not enhance the neutralization rate of factor VIIa-tissue factor by antithrombin III-heparin when a carboxyl-terminal truncated tissue factor construct (TF1-219) was used, even in the presence of mixed phospholipids. Our collective finding suggest that antithrombin III and factor X bind to heparin at distinct sites on the heparin molecule resulting in a transient ternary complex of antithrombin III-heparin-factor X that represents the anticoagulant species. Factor X conceivably guides complex to a phosphatidylserine-rich site on the cell surface in close proximity to the factor VIIa-tissue factor complex and facilitates rapid neutralization of factor VIIa. Our findings also suggest that the effect of heparin on the regulation of the extrinsic pathway of blood coagulation may be more profound than previously recognized.
先前的研究表明,抗凝血酶III - 肝素可有效抑制因子VIIa - 组织因子复合物。在此,我们发现血浆中的因子X可显著增强抗凝血酶III - 肝素对与细胞表面组织因子结合的因子VIIa的中和作用。活性位点突变的因子X(S376A因子X)和先前用丹磺酰 - 谷氨酸 - 甘氨酸 - 精氨酸 - 氯甲基酮灭活的因子Xa在该反应中与血浆来源的因子X一样有效,这表明因子Xa的活性位点丝氨酸残基不参与该机制。此外,无Gla结构域的因子X在该系统中无作用,这强调了因子X的Gla结构域在该反应中的重要性。抗体实验表明,这种作用并非由于因子X或抗凝血酶III制剂中污染的微量组织因子途径抑制剂所致。该系统中肝素的存在至关重要,因为去除肝素会导致因子VIIa - 组织因子的中和速率与单独观察到的抗凝血酶III的中和速率基本相同。血浆中的因子IX也加速了抗凝血酶III - 肝素对因子VIIa - 组织因子的抑制作用,尽管其作用不如因子X明显。其他维生素K依赖性血浆蛋白,包括蛋白S、蛋白C和凝血酶原,未能增强抗凝血酶III - 肝素对因子VIIa - 组织因子的抑制作用。当使用羧基末端截短的组织因子构建体(TF1 - 219)时,即使存在混合磷脂,因子X也不会增强抗凝血酶III - 肝素对因子VIIa - 组织因子的中和速率。我们的总体发现表明,抗凝血酶III和因子X在肝素分子上的不同位点与肝素结合,形成抗凝血酶III - 肝素 - 因子X的瞬时三元复合物,该复合物代表抗凝物质。可以想象,因子X将复合物引导至细胞表面富含磷脂酰丝氨酸的位点,该位点紧邻因子VIIa - 组织因子复合物,并促进因子VIIa的快速中和。我们的发现还表明,肝素对血液凝固外源性途径的调节作用可能比先前认识到的更为深远。